ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094 is a follow-up study in adult male subjects who have received investigational product (either dutasteride or placebo) in the REDUCE Study (REduction by DUasteride of prostate Cancer Events), ARI40006, A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer. There are 2 parts to this REDUCE Follow-Up Study, Part A and Part B:
Inclusion Criteria: PART A
Exclusion Criteria: PART A Subjects meeting the following criterion must not be enrolled in Part A of the study
Inclusion Criteria: PART B
Subjects eligible for enrolment in Part B of the study must meet the following criteria:
Exclusion Criteria: PART B
Av Córdoba 2424, Buenos Aires 1120, Argentina
Capital Federal, Buenos Aires 1437, Argentina
Capital Federal, Buenos Aires C1121AAF, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1405BCH, Argentina
Hagenow, Brandenburg 19230, Germany
Galdakano, 48960, Spain
La Laguna-Tenerife, 38320, Spain
Clydebank, Glasgow, G81 2DR, United Kingdom
Edgbaston, Birmingham, B15 2SQ, United Kingdom
High Heaton, Newcastle Upon Tyne, NE7 7PN, United Kingdom
Waterloo, Liverpool, L22 0LG, United Kingdom